Eli Lilly and Company (NYSE:LLY) Trading Down 5.9% Following Analyst Downgrade

Key Points

• Shares fell 5.9% intraday after HSBC downgraded LLY to "reduce" and cut its price target to $850 (from $1,070), a sell‑off driven by concerns about pricing pressure, rising competition and optimistic obesity‑drug assumptions; volume surged about 74% with the stock trading as low as $925.25.
• That weakness contrasts with continued bullish views from other firms—JPMorgan, Jefferies and Barclays recently set targets of roughly $1,300–$1,350—and MarketBeat's consensus remains a Moderate Buy with an average target near $1,221, supported by strong Q results (EPS $7.54, revenue $19.29B, up 42.6%) and FY2026 guidance of $33.50–$35.00 EPS.

Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) traded down 5.9% on Tuesday after HSBC downgraded the stock from a hold rating to a reduce rating. HSBC now has a $850.00 price target on the stock, down from their previous price target of $1,070.00. Eli Lilly and Company traded as low as $925.25 and last traded at $931.0270. 5,600,775 shares were traded during trading, an increase of 74% from the average session volume of 3,216,031 shares. The stock had previously closed at $989.12.

LLY has been the topic of a number of other reports. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an "overweight" rating in a research report on Thursday, February 5th. Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the stock a "buy" rating in a report on Friday. Berenberg Bank raised their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a "hold" rating in a report on Thursday, February 19th. Daiwa Securities Group upped their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a "buy" rating in a report on Wednesday, February 18th. Finally, Barclays initiated coverage on shares of Eli Lilly and Company in a report on Thursday, February 19th. They set an "overweight" rating and a $1,350.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,221.44.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Positive pediatric Phase‑3 data for EBGLYSS (lebrikizumab) — topline results showed strong skin‑clearance and itch relief in children, supporting a potential label expansion that strengthens Lilly’s immunology/dermatology growth optionality. Lilly EBGLYSS PR Newswire
• Positive Sentiment: Some Wall Street firms remain bullish — several firms reiterated Outperform/Buy views and high price targets based on continued GLP‑1 momentum and expansion initiatives (Employer Connect, pre‑launch inventory for oral pill). This provides counterweight to near‑term concerns. Wall Street Firms Turn Bullish (Yahoo)
• Neutral Sentiment: Congressional disclosure: a lawmaker reported a purchase of LLY in late February — a data point that highlights continued interest in the GLP‑1 theme but is not a timely trading signal given disclosure delays. Members of Congress Bought These 5 Stocks (MarketBeat)
• Negative Sentiment: HSBC downgraded LLY to “reduce” and cut its price target to $850, citing pricing pressure, rising competition and overly optimistic assumptions about obesity‑drug market growth — the downgrade is the primary immediate catalyst for today’s sell‑off. Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations (Benzinga)
• Negative Sentiment: Competitive pressures mounting: reports on FDA timing/decisions around oral obesity pills and strong mid‑stage results from rivals (e.g., Structure Therapeutics’ GLP‑1 pill) reinforce the risk that pricing and market share gains could be constrained. Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision (24/7 Wall St.)

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently bought and sold shares of the business. Maryland Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $25,000. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $30,000. Miller Global Investments LLC bought a new position in Eli Lilly and Company during the fourth quarter worth $33,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its position in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after acquiring an additional 24 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 5.9%

The firm's 50-day moving average price is $1,036.20 and its 200 day moving average price is $954.12. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The company has a market capitalization of $879.65 billion, a price-to-earnings ratio of 40.57, a PEG ratio of 1.15 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the prior year, the company earned $5.32 EPS. The firm's revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.